This device is commercially available for use in select international markets.
Respect the Flow
The HeartMate 3™ left ventricular assist system (LVAS) is designed to provide mechanical circulatory support to a broad range of advanced heart failure patients. Building on proven results from the CentriMag™ Pumps, the HeartMate 3 LVAS employs Full MagLev™ flow technology designed to optimize hemocompatibility and reduce blood trauma through gentle blood handling.
In the CE Mark clinical trial, the HeartMate 3 LVAS patients had a 98-percent survival rate at 30 days and 92 percent at 6 months.1 Most saw significant improvements in symptom reduction and quality of life.1
The HeartMate 3 LVAS is indicated for destination therapy, bridge-to-transplantation and myocardial recovery.
Building comprehensive heart failure management
The HeartMate 3™ LVAS is part of our heart failure management portfolio. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about the portfolio and our approach to heart failure management.